The evolving landscape of immunohistochemistry in cervical and uterine carcinoma in gynecologic oncology: current status and future directions

키워드

참고문헌 (74)

1. "Protocol for the examination of resection specimens from patients with primary carcinoma of the uterine cervix" (2020)[URL]
2. Bhatla N, "Revised FIGO staging for carcinoma of the cervix uteri", Int J Gynaecol Obstet, 145, pp.129~135 (2019)
3. Stolnicu S, "International endocervical adenocarcinoma criteria and classification(IECC) : a new pathogenetic classification for invasive adenocarcinomas of the endocervix", Am J Surg Pathol, 42, pp.214~226 (2018)
4. Diaz De Vivar A, "Invasive endocervical adenocarcinoma : proposal for a new pattern-based classification system with significant clinical implications : a multi-institutional study", Int J Gynecol Pathol, 32, pp.592~601 (2013)
5. Yemelyanova A, "Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas : utility of HPV DNA detection and immunohistochemical expression of p16and hormone receptors to confirm the cervical origin of the corpus tumor", Am J Surg Pathol, 33, pp.914~924 (2009)
6. Chiesa-Vottero AG, "Immunohistochemical overexpression of p16 and p53 in uterine serous carcinoma and ovarian high-grade serous carcinoma", Int J Gynecol Pathol, 26, pp.328~333 (2007)
7. McCluggage WG, "Metastatic carcinomas in the cervix mimicking primary cervical adenocarcinoma and adenocarcinoma in situ : report of a series of cases", Am J Surg Pathol, 34, pp.735~741 (2010)
8. Glenn McCluggage W, "Immunohistochemistry as a diagnostic aid in cervical pathology", Pathology, 39, pp.97~111 (2007)
9. McCluggage WG, "A panel of immunohistochemical stains, including carcinoembryonic antigen, vimentin, and estrogen receptor, aids the distinction between primary endometrial and endocervical adenocarcinomas", Int J Gynecol Pathol, 21, pp.11~15 (2002)
10. Staebler A, "Hormone receptor immunohistochemistry and human papillomavirus in situ hybridization are useful for distinguishing endocervical and endometrial adenocarcinomas", Am J Surg Pathol, 26, pp.998~1006 (2002)
11. Nofech-Mozes S, "Immunophenotyping of serous carcinoma of the female genital tract", Mod Pathol, 21, pp.1147~1155 (2008)
12. Roma AA, "New pattern-based personalized risk stratification system for endocervical adenocarcinoma with important clinical implications and surgical outcome", Gynecol Oncol, 141, pp.36~42 (2016)
13. Talia KL, "The developing spectrum of gastric-type cervical glandular lesions", Pathology, 50, pp.122~133 (2018)
14. Zhao S, "Mucin expression in nonneoplastic and neoplastic glandular epithelia of the uterine cervix", Int J Gynecol Pathol, 22, pp.393~397 (2003)
15. Lee S, "Tissue-based immunohistochemical biomarker expression in malignant glandular lesions of the uterine cervix : a systematic review", Int J Gynecol Pathol, 37, pp.128~140 (2018)
16. Carleton C, "A detailed immunohistochemical analysis of a large series of cervical and vaginal gastric-type adenocarcinomas", Am J Surg Pathol, 40, pp.636~644 (2016)
17. Howitt BE, "GATA3 is a sensitive and specific marker of benign and malignant mesonephric lesions in the lower female genital tract", Am J Surg Pathol, 39, pp.1411~1419 (2015)
18. Roma AA, "Differential expression patterns of GATA3 in uterine mesonephric and nonmesonephric lesions", Int J Gynecol Pathol, 34, pp.480~486 (2015)
19. Ju B, "Morphologic and immunohistochemical study of clear cell carcinoma of the uterine endometrium and cervix in comparison to ovarian clear cell carcinoma", Int J Gynecol Pathol, 37, pp.388~396 (2018)
20. Spaans VM, "Independent validation of the prognostic significance of invasion patterns in endocervical adenocarcinoma : pattern a predicts excellent survival", Gynecol Oncol, 151, pp.196~201 (2018)
21. Rindi G, "A common classification framework for neuroendocrine neoplasms : an International Agency for Research on Cancer(IARC)and World Health Organization(WHO)expert consensus proposal", Mod Pathol, 31, pp.1770~1786 (2018)
22. Howitt BE, "Pathology of neuroendocrine tumours of the female genital tract", Curr Oncol Rep, 19, pp.59~ (2017)
23. Ganesan R, "Neuroendocrine carcinoma of the cervix : review of a series of cases and correlation with outcome", Int J Surg Pathol, 24, pp.490~496 (2016)
24. "Small cell neuroendocrine carcinoma" (2024)[URL]
25. Huang W, "PD-1", PD-L1 inhibitors for advanced or metastatic cervical cancer : from bench to bed, 2022, pp.12, 849352~
26. Lantuejoul S, "PD-L1 testing for lung cancer in 2019 : perspective from the IASLC pathology committee", J Thorac Oncol, 15, pp.499~519 (2020)
27. Han Y, "PD-1", PD-L1 pathway : current researches in cancer, 2020, pp.10, 727~742
28. Ansari-Lari MA, "Distinction of endocervical and endometrial adenocarcinomas : immunohistochemical p16 expression correlated with human papillomavirus(HPV)DNA detection", Am J Surg Pathol, 28, pp.160~167 (2004)
29. Kong CS, "A panel of 3 markers including p16, ProExC, or HPV ISH is optimal for distinguishing between primary endometrial and endocervical adenocarcinomas", Am J Surg Pathol, 34, pp.915~926 (2010)
30. Saad RS, "P16INK4a expression in undifferentiated carcinoma of the uterus does not exclude its endometrial origin", Int J Gynecol Pathol, 31, pp.57~65 (2012)
31. McCluggage WG, "Patterns of p53 immunoreactivity in endometrial carcinomas : ‘all or nothing’ staining is of importance", Histopathology, 59, pp.786~788 (2011)
32. Houghton O, "The expression and diagnostic utility of p63 in the female genital tract", Adv Anat Pathol, 16, pp.316~321 (2009)
33. Bartosch C, "Endometrial carcinomas : a review emphasizing overlapping and distinctive morphological and immunohistochemical features", Adv Anat Pathol, 18, pp.415~437 (2011)
34. Gilks CB, "Poor interobserver reproducibility in the diagnosis of high-grade endometrial carcinoma", Am J Surg Pathol, 37, pp.874~881 (2013)
35. Laury AR, "A comprehensive analysis of PAX8 expression in human epithelial tumors", Am J Surg Pathol, 35, pp.816~826 (2011)
36. Ordóñez NG, "Value of PAX 8 immunostaining in tumor diagnosis : a review and update", Adv Anat Pathol, 19, pp.140~151 (2012)
37. Nonaka D, "Expression of pax8as a useful marker in distinguishing ovarian carcinomas from mammary carcinomas", Am J Surg Pathol, 32, pp.1566~1571 (2008)
38. Shukla A, "PAX8 and PAX2 expression in endocervical adenocarcinoma in situ and high-grade squamous dysplasia", Int J Gynecol Pathol, 32, pp.116~121 (2013)
39. Köbel M, "Interpretation of P53 immunohistochemistry in endometrial carcinomas : toward increased reproducibility", Int J Gynecol Pathol, 38(Suppl 1:), pp.S123~S131 (2019)
40. Baniak N, "Targeted molecular and immunohistochemical analyses of endometrial clear cell carcinoma show that POLE mutations and DNA mismatch repair protein deficiencies are uncommon", Am J Surg Pathol, 43, pp.531~537 (2019)
41. Chen W, "Immunohistochemical profiling of endometrial serous carcinoma", Int J Gynecol Pathol, 36, pp.128~139 (2017)
42. Kommoss F, "Uterine serous carcinomas frequently metastasize to the fallopian tube and can mimic serous tubal intraepithelial carcinoma", Am J Surg Pathol, 41, pp.161~170 (2017)
43. McNamara B, "HER2 oncogene as molecular target in uterine serous carcinoma and uterine carcinosarcoma", Cancers(Basel), 15, pp.4085~ (2023)
44. Glasspool RM, "Clear cell carcinoma of ovary and uterus", Curr Oncol Rep, 15, pp.566~572 (2013)
45. Fadare O, "Diagnostic utility of hepatocyte nuclear factor 1-beta immunoreactivity in endometrial carcinomas : lack of specificity for endometrial clear cell carcinoma", Appl Immunohistochem Mol Morphol, 20, pp.580~587 (2012)
46. Fadare O, "Comparative analysis of Napsin A, alphamethylacyl-coenzyme A racemase(AMACR, P504S), and hepatocyte nuclear factor 1 beta as diagnostic markers of ovarian clear cell carcinoma : an immunohistochemical study of 279 ovarian tumours", Pathology, 47, pp.105~111 (2015)
47. Hariri N, "Endometrial serous carcinoma with clear-cell change : frequency and immunohistochemical analysis", Int J Surg Pathol, 26, pp.126~134 (2018)
48. Li Z, "Clinicopathologic and immunohistochemical characterization of dedifferentiated endometrioid adenocarcinoma", Appl Immunohistochem Mol Morphol, 24, pp.562~568 (2016)
49. Tafe LJ, "Endometrial and ovarian carcinomas with undifferentiated components : clinically aggressive and frequently underrecognized neoplasms", Mod Pathol, 23, pp.781~789 (2010)
50. Shah VI, "CD34 expression in undifferentiated endometrial carcinoma", Histopathology, 69, pp.894~897 (2016)
51. Ramalingam P, "Loss of expression of SMARCA4(BRG1), SMARCA2(BRM)and SMARCB1(INI1)in undifferentiated carcinoma of the endometrium is not uncommon and is not always associated with rhabdoid morphology", Histopathology, 70, pp.359~366 (2017)
52. Tipps AM, "Endometrioid carcinoma with a low-grade spindle cell component : a tumor resembling an adnexal tumor of probable Wolffian origin", Ann Diagn Pathol, 15, pp.376~381 (2011)
53. Stewart AP, "Genetic testing strategies in newly diagnosed endometrial cancer patients aimed at reducing morbidity or mortality from lynch syndrome in the index case or her relatives", PLoS Curr, 5 (2013)
54. Watkins JC, "Unusual mismatch repair immunohistochemical patterns in endometrial carcinoma", Am J Surg Pathol, 40, pp.909~916 (2016)
55. Pai RK, "Abrupt loss of MLH1 and PMS2expression in endometrial carcinoma : molecular and morphologic analysis of 6 cases", Am J Surg Pathol, 39, pp.993~999 (2015)
56. van den Heerik ASVM, "Adjuvant therapy for endometrial cancer in the era of molecular classification : radiotherapy, chemoradiation and novel targets for therapy", Int J Gynecol Cancer, 31, pp.594~604 (2021)
57. Ogunmuyiwa J, "Emerging advances in endometrial cancer : integration of molecular classification into staging for enhanced prognostic accuracy and implications for racial disparities", Cancers(Basel), 16, pp.1172~ (2024)
58. Oliva E, "Practical issues in uterine pathology from banal to bewildering: the remarkable spectrum of smooth muscle neoplasia", Mod Pathol, 29(Suppl 1), pp.S104~S120 (2016)
59. Zhang Q, "The selected biomarker analysis in 5 types of uterine smooth muscle tumors", Hum Pathol, 76, pp.17~27 (2018)
60. Hakverdi S, "Immunohistochemical analysis of p16 expression in uterine smooth muscle tumors", Eur J Gynaecol Oncol, 32, pp.513~515 (2011)
61. Hoang LN, "Novel high-grade endometrial stromal sarcoma : a morphologic mimicker of myxoid leiomyosarcoma", Am J Surg Pathol, 41, pp.12~24 (2017)
62. Parra-Herran C, "Myxoid leiomyosarcoma of the uterus : a clinicopathologic analysis of 30 cases and review of the literature with reappraisal of its distinction from other uterine myxoid mesenchymal neoplasms", Am J Surg Pathol, 40, pp.285~301 (2016)
63. Parra-Herran C, "Inflammatory myofibroblastic tumor of the uterus : clinical and pathologic review of 10 cases including a subset with aggressive clinical course", Am J Surg Pathol, 39, pp.157~168 (2015)
64. O’Neill CJ, "Uterine leiomyosarcomas are characterized by high p16, p53 and MIB1 expression in comparison with usual leiomyomas, leiomyoma variants and smooth muscle tumours of uncertain malignant potential", Histopathology, 50, pp.851~858 (2007)
65. Hwang H, "Immunohistochemical panel to differentiate endometrial stromal sarcoma, uterine leiomyosarcoma and leiomyoma : something old and something new", J Clin Pathol, 68, pp.710~717 (2015)
66. Micci F, "Cytogenetic and molecular profile of endometrial stromal sarcoma", Genes Chromosomes Cancer, 55, pp.834~846 (2016)
67. Isphording A, "YWHAE-FAM22 endometrial stromal sarcoma : diagnosis by reverse transcription-polymerase chain reaction in formalin-fixed, paraffin-embedded tumor", Hum Pathol, 44, pp.837~843 (2013)
68. Lee CH, "The clinicopathologic features of YWHAEFAM22endometrial stromal sarcomas : a histologically high-grade and clinically aggressive tumor", Am J Surg Pathol, 36, pp.641~653 (2012)
69. Conlon N, "Perivascular epithelioid tumours(PEComas)of the gynaecological tract", J Clin Pathol, 68, pp.418~426 (2015)
70. Folpe AL, "Perivascular epithelioid cell neoplasms of soft tissue and gynecologic origin : a clinicopathologic study of 26 cases and review of the literature", Am J Surg Pathol, 29, pp.1558~1575 (2005)
71. Rao Q, "Cathepsin K expression in a wide spectrum of perivascular epithelioid cell neoplasms(PEComas) : a clinicopathological study emphasizing extrarenal PEComas", Histopathology, 62, pp.642~650 (2013)
72. Gulavita P, "PNL2 : an adjunctive biomarker for renal angiomyolipomas and perivascular epithelioid cell tumours", Histopathology, 72, pp.441~448 (2018)
73. Bennett JA, "Inflammatory myofibroblastic tumor of the uterus : a clinicopathological, immunohistochemical, and molecular analysis of 13 cases highlighting their broad morphologic spectrum", Mod Pathol, 30, pp.1489~1503 (2017)
74. Haimes JD, "Uterine inflammatory myofibroblastic tumors frequently harbor ALK fusions with IGFBP5 and THBS1", Am J Surg Pathol, 41, pp.773~780 (2017)

관련 논문AI추천